Gastrointestinal adverse effects (nausea, vomiting, diarrhoea) occur at similar frequencies to other GLP-1 receptor agonists, affecting approximately 12% to 24% of patients (nausea being most common), and are typically more frequent during dose escalation
No dose adjustment is recommended for any stage of renal or hepatic impairment, though monitoring renal function is advised if significant gastrointestinal adverse effects occur
The results warrant caution with carrageenan-containing foods, especially in individuals who are prone to develop type 2 diabetes . Journal reference: Wagner, R., Buettner, J., Heni, M., et al
Our supplement is vegan, non-GMO, and free from dairy, soy, and gluten, making it perfect for various dietary needs